Cellular Validation of a Chemically Improved Inhibitor Identifies Monoubiquitination on OTUB2.Gan, J., de Vries, J., Akkermans, J.J.L.L., Mohammed, Y., Tjokrodirijo, R.T.N., de Ru, A.H., Kim, R.Q., Vargas, D.A., Pol, V., Fasan, R., van Veelen, P.A., Neefjes, J., van Dam, H., Ovaa, H., Sapmaz, A., Geurink, P.P.
(2023) ACS Chem Biol 18: 2003-2013
- PubMed: 37642399
- DOI: https://doi.org/10.1021/acschembio.3c00227
- Primary Citation of Related Structures:
- PubMed Abstract:
Ubiquitin thioesterase OTUB2, a cysteine protease from the ovarian tumor (OTU) deubiquitinase superfamily, is often overexpressed during tumor progression and metastasis. Development of OTUB2 inhibitors is therefore believed to be therapeutically important, yet potent and selective small-molecule inhibitors targeting OTUB2 are scarce. Here, we describe the development of an improved OTUB2 inhibitor, LN5P45 , comprising a chloroacethydrazide moiety that covalently reacts to the active-site cysteine residue. LN5P45 shows outstanding target engagement and proteome-wide selectivity in living cells. Importantly, LN5P45 as well as other OTUB2 inhibitors strongly induce monoubiquitination of OTUB2 on lysine 31. We present a route to future OTUB2-related therapeutics and have shown that the OTUB2 inhibitor developed in this study can help to uncover new aspects of the related biology and open new questions regarding the understanding of OTUB2 regulation at the post-translational modification level.
Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZC Leiden, The Netherlands.